Valeant plans to sweeten bid for Allergan

Valeant (VRX) intends to its improve its $45.7B offer for Allergan (AGN) based of feedback that the Canadian company hopes to receive from Allergan shareholders during a Webcast about the deal on May 28.

"We are prepared to pay a full and fair price, but, consistent with our track record, we will remain financially disciplined," Valeant said.

The firm's comments come after Allergan formally rejected Valeant's proposal yesterday.

Allergan's shares are +1.9% premarket. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs